NHS supports selected use of inhaled budesonide for COVID-19 in people at risk of severe events
1 August 2021. Related: COVID-19: investigational drugs, COVID-19.
COVID-19: investigational drugs
Reviews of ivermectin for COVID-19: evidence from RCTs is still needed
1 August 2021. Related: COVID-19: investigational drugs, COVID-19.
RCT shows no impact of azithromycin in reducing symptoms of mild COVID-19
1 August 2021. Related: COVID-19: investigational drugs, COVID-19.
Research approach to rapidly review candidate treatments for COVID-19: nine studies using ACTIV protocol
1 July 2021. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.
COVID-19 treatment: tofacitinib, REGN bNAbs, convalescent plasma
1 July 2021. Related: COVID-19: investigational drugs, COVID-19.
Dexamethasone: final results from RECOVERY study
3 May 2021. Related: COVID-19: investigational drugs, COVID-19.
No impact from anakinra in mild/moderate COVID-19 pneumonia
3 May 2021. Related: COVID-19: investigational drugs, COVID-19.
CROI 2021: New compounds for prevention and treatment of COVID-19
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
Tocilizimab effectively reduces COVID-19 related deaths and hospitalisation time: additive benefit with dexamethasone
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
US FDA specifies high antibody titre for convalescent plasma and to only use in early COVID-19
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from convalescent plasma in UK RECOVERY study: limited results restrict implications for COVID-19
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment
22 January 2021. Related: COVID-19: vaccine research, COVID-19: investigational drugs, COVID-19.
Oral colchicine reduces hospitalisation in international randomised phase 3 outpatient study
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
IL-6 agonists tocilizumab and sarilumab reduces mortality in severe COVID-19: interim results from REMAP-CAP study
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
Two different dual antibody treatments each reduce SARS-CoV-2 viral load by >0.5 log
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
IV methylprednisolone pulse treatment for hospitalised severe COVID-19
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
Azithromycin monotherapy shows no benefit for COVID-19: RECOVERY study reports 1493 further deaths
22 January 2021. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.
Hydroxychloroquine fails to prevent COVID-19 or SARS-CoV-2 transmission when used as PEP
9 December 2020. Related: COVID-19: investigational drugs, COVID-19: transmission & prevention, COVID-19.
Hydroxychloroquine has no benefit on symptoms at 14 days
9 December 2020. Related: COVID-19: investigational drugs, COVID-19.
WHO SOLIDARITY study published in NEJM
9 December 2020. Related: COVID-19: investigational drugs, COVID-19.
International COVID-19 study launches in Africa but with drugs that have little chance of working (ANTICOV)
9 December 2020. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.
Remdesivir given full approval by the US FDA, but on limited data
11 November 2020. Related: COVID-19: investigational drugs, COVID-19.
DSMB stops REGN-COV2 (casirivimab/imdevimab) monoclonal antibody study in people with high-flow oxygen or ventilation: implications for UK RECOVERY study
11 November 2020. Related: COVID-19: investigational drugs, COVID-19.
Monoclonal antibody stopped in ACTIV-3 study: bamlanivimab shows lack of benefit in people hospitalised with COVID-19
11 November 2020. Related: COVID-19: investigational drugs, COVID-19.
Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19
11 November 2020. Related: COVID-19: investigational drugs, COVID-19.
No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study
11 November 2020. Related: COVID-19: investigational drugs, COVID-19.
COVID-19: pathogenesis and treatment
14 October 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue
14 October 2020. Related: COVID-19: investigational drugs, COVID-19.
Tocilizumab associated with better outcomes from COVID-19 in US study
28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
Famotidine associated with better outcomes from COVID-19
28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555
28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Predictors of response to remdesivir in GS-5773 COVID-19 study
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
EMA grants conditional approval for remdesivir in the EU to treat COVID-19
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Individualising management of COVID-19 based on real-time inflammatory responses
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Further positive reports from tocilizumab to treat COVID-19
22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers
26 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit
1 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Convalescent plasma therapy for COVID-19
1 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Treatment with interferon in early COVID-19
1 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Famotidine associated with improved clinical outcomes in people hospitalised with COVID-19
1 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Tocilizumab and remdesivir in new dual therapy study
1 June 2020. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.
RETRACTED – Re: No benefit from hydroxychloroquine, with or without macrolide antibiotics in analysis of 96,000 patients
1 June 2020. Related: COVID-19: investigational drugs, COVID-19.
Remdesivir for COVID-19: randomised study shows similar antiviral effect to placebo
14 May 2020. Related: COVID-19: investigational drugs, COVID-19.
Other remdesivir news: top results from NIH and Gilead studies – emergency approval in US and Japan
14 May 2020. Related: COVID-19: investigational drugs, COVID-19.
Potential for tocilizumab to treat moderate to severe COVID-19
14 May 2020. Related: COVID-19: investigational drugs, COVID-19.
Detectable viral load and IL-6: a role for tocilizumab or anti-JAK inhibitor baricitinib?
14 May 2020. Related: COVID-19: investigational drugs, COVID-19.